Arrowhead Pharmaceuticals: Strategic Move with FDA Priority Review Voucher
Arrowhead Pharmaceuticals secures FDA Priority Review Voucher for plozasiran, aiming to expedite its supplemental NDA filing.
Eli Lilly's Stellar Earnings and Breakthrough Therapy Status: A Game Changer for Investors
Eli Lilly's earnings beat and FDA milestone could redefine its market trajectory.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Arrowhead Pharmaceuticals' Strategic Acquisition: Priority Review Voucher for Plozasiran
Arrowhead's acquisition of a Priority Review Voucher is set to reshape its market strategy and impact its stock.
Eton Pharmaceuticals Expands Portfolio with ASN-001 Acquisition
Eton Pharmaceuticals enhances its pipeline with the acquisition of ASN-001, targeting the infantile hemangioma market.
Bullish Surge: Nasdaq 100 Signals Market Optimism
The Nasdaq 100's top-10 bullish signal marks a pivotal moment for traders, with tech stocks leading a significant market…
Johnson & Johnson's Robotic Surgery Breakthrough: A Game Changer for Investors
FDA approval of J&J's OTTAVA system sparks optimism, positioning the company as a strong contender in surgical robotics.
Palantir's AI Surge: What Investors Need to Know After Q2 Earnings
Palantir's Q2 earnings show a strong 16% share price increase and highlight growing demand for enterprise AI.
Pfizer's Strategic Shift: Navigating Beyond Covid Revenue
Pfizer's recent Q2 earnings reflect a pivot to non-Covid products as Covid revenue expectations are reduced.
Sunshine Biopharma's New Drug Approval: A Strategic Move into Women's Health
Sunshine Biopharma's approval of a generic drug opens doors to a lucrative women's health market worth $5.2 billion.
Palantir's AI Surge: What It Means for Tech Investors
Palantir's shares rose 16% after strong Q2 earnings, indicating robust demand for AI solutions.
Pfizer's Q2 Earnings Beat: A Post-Pandemic Perspective
Pfizer's Q2 earnings exceeded expectations, signaling strong performance from non-COVID products amid adjusted revenue f…